Introduction

Managing diffuse coronary lesions in diabetic patients remains a significant clinical challenge for interventional cardiologists. Recent evidence suggests that using DCB in diabetic SVD offers a viable alternative to traditional stenting. Unlike drug-eluting stents (DES), drug-coated balloons (DCB) provide a \"leave-nothing-behind\" strategy. This approach avoids the complications associated with permanent metallic scaffolds, such as chronic inflammation and late stent thrombosis.

Clinical Advantages of DCB in Diabetic SVD

Physicians often prefer DCBs in small vessels because they allow for more uniform drug delivery. Diabetics frequently suffer from impaired endothelial healing and exaggerated neointimal proliferation. Consequently, traditional stents in vessels smaller than 3 mm often lead to higher rates of restenosis. DCB technology addresses this by promoting better vascular healing without leaving a foreign body in the artery. Furthermore, DCB angioplasty preserves the natural vasoreactivity of the coronary vessels, which is vital for long-term physiological health.

Trial Evidence and Outcomes

Several major trials have validated the safety of this intervention. For instance, the BASKET-SMALL 2 trial demonstrated that DCBs are non-inferior to second-generation DES in terms of major adverse cardiac events (MACE). Notably, subgroup analyses focused on diabetic patients showed even more promising results. In these patients, DCBs significantly reduced the need for target vessel revascularization (TVR) compared to stents. Additionally, meta-analyses from late 2024 and 2025 confirm that DCBs achieve superior angiographic outcomes, specifically regarding late lumen loss and binary restenosis.

Procedural Benefits and DAPT Duration

Another critical advantage of the DCB strategy involves the duration of dual antiplatelet therapy (DAPT). Diabetic patients often carry a high risk of both ischemic and bleeding events. Because DCBs do not leave a metallic scaffold, clinicians can safely shorten the DAPT duration to as little as four weeks. This reduction significantly lowers the risk of major bleeding complications without compromising procedural success. Modern sirolimus-coated technology further enhances these outcomes by providing more stable drug transfer and sustained antiproliferative effects.

Frequently Asked Questions

What are the primary benefits of DCB in diabetic SVD over traditional stents?

DCBs eliminate the risk of late stent thrombosis and chronic inflammation by avoiding a permanent metallic scaffold. They also allow for a significantly shorter DAPT duration, which is crucial for diabetic patients at high risk of bleeding.

Which trials support the use of DCB for diabetic patients?

Key trials include BELLO, BASKET-SMALL 2, and PICCOLETO II. These studies consistently show that DCB is non-inferior to DES in small vessels, with some data suggesting lower rates of revascularization in diabetic subgroups.

Does the type of drug coating matter for small vessel disease?

While paclitaxel-coated balloons have the most historical data, newer sirolimus-coated balloons are showing excellent results. Current research suggests sirolimus may offer better safety profiles and effective neointimal suppression in diabetic patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. It should not be used for self-diagnosis or as a substitute for professional medical consultation. Refer to the latest local and national guidelines for clinical practice.

References

Tsiamis N et al. Revolutionizing Modern Percutaneous Coronary Intervention: Drug-Coated Balloons for Diabetics With Small Vessel Disease. A Narrative Review. Catheter Cardiovasc Interv. 2026 Mar 15. doi: 10.1002/ccd.70550. PMID: 41833545.

Wöhrle J et al. Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents: the BASKET-SMALL 2 trial. JACC Cardiovasc Interv. 2021;14(16):1789-1798.

Angheluta AD et al. A Meta-Analysis of 3-Year Outcomes of Drug-Coated Balloons Versus Drug-Eluting Stents for Small-Vessel Coronary Artery Disease. JACC Adv. 2024;3(10):101204.